Gd-EOB-DTPA disodium; ZK 139834 MedChemExpress (MCE)

Product Name	GADOXETATE DISODIUM
Synonyms	ZK 139834;Gadoxetate;Gadoxetatesodium;gadoliniuM coMplex;GADOXETATE DISODIUM;3Gadoxetate disodium;Gd-EOB-DTPA (Disodium);Gadoxetate Disodium Salt (Mixture ofDiastereomers)
CAS	135326-22-6
EINECS
Chemical Formula	C23H28GdN3Na2O11
Molecular Weight	725.71146
inchi
Package	1 mg;5 mg;10 mg;25 mg;50 mg;100 mg
Price	Get quote
Descriptions	Gadoxetate disodium Gadoxetate disodium MedChemExpress (MCE) HY-16219 135326-22-6 Gd-EOB-DTPA disodium Descriptions Gadoxetate disodium Gadoxetate disodium MedChemExpress (MCE) HY-16219 135326-22-6 Gd-EOB-DTPA disodium ZK 139834 99.97% 4°C, sealed storage, away from moisture In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) Room temperature in continental US may vary elsewhere. Gadoxetate (Gd-EOB-DTPA) Disodium is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system, which accumulates in normal, functioning hepatocytes. Gadoxetate Disodium aggravates liver fibrosis (LF) induced gadolinium deposition in the liver and deep cerebellar nuclei (DCN) of rats without significant acute histological alterations. Gadoxetate Disodium is used to evaluate focal liver lesions, such as hepatocellular carcinoma or dysplastic nodules. Gadoxetate Disodium (0.625 mmol/kg, i.v., 5 days) combined with liver fibrosis (LF) aggravates gadolinium deposition, but results no significant histopathological change in the liver and deep cerebellar nuclei (DCN) of rats[6]. \| \| \| \| \| \| \| \| \| \| [1]. Schuhmann-Giampieri G, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992 Apr 183(1):59-64. [Content Brief]* [2]. Katsube T, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011 Apr 46(4):277-83. [Content Brief] [3]. Saito K, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005 4(1):1-9. [Content Brief] [4]. Chernyak V, et al. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)[J]. J Magn Reson Imaging. 2019 May 49(5):1236-1252. [Content Brief] [5]. Huh J, et al. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver[J]. Korean J Radiol. 2015 Nov-Dec 16(6):1207-15. [Content Brief] [6]. Wei P, et al. Gadolinium deposition in the liver and brain in a rat model with liver fibrosis after intravenous administration of gadoxetate disodium[J]. Heliyon. 2024 Mar 8 10(6):e27419. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact